Profil
Jakub Klimes has worked as the Head of Operations at HealthMode, Inc. since 2019.
Postes actifs de Jakub Klimes
| Sociétés | Poste | Début |
|---|---|---|
HealthMode, Inc.
 HealthMode, Inc. Packaged SoftwareTechnology Services Part of Mind Medicine (MindMed), Inc., HealthMode, Inc. drives progression to next-generation clinical trials by developing and delivering AI-enabled digital measurement methods for clinical trials. The company is based in San Francisco, CA. HealthMode's measurement techniques improve understanding of phenotype, streamline and provide assurance for screening and eligibility, provide early detection and mitigation of adverse events, and serve as sensitive, specific, objective, and low participant burden efficacy endpoints. These measurements allow for meaningful integration of clinical trial data with real-world evidence, and provide the basis for movement toward patient-specific measures. Better measurement tools and the platforms to support them help HealthMode's partners make data-informed decisions, reduce uncertainty around enrollment and outcomes, de-risk development, and increase the speed at which novel therapeutics reach patients in need. The company was founded by Bradford Cross, Daniel R. Karlin. HealthMode was acquired by Mind Medicine (MindMed), Inc. on February 26, 2021 for $41.54 million. | Directeur des opérations | 01/05/2019 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
HealthMode, Inc.
HealthMode, Inc. Packaged SoftwareTechnology Services Part of Mind Medicine (MindMed), Inc., HealthMode, Inc. drives progression to next-generation clinical trials by developing and delivering AI-enabled digital measurement methods for clinical trials. The company is based in San Francisco, CA. HealthMode's measurement techniques improve understanding of phenotype, streamline and provide assurance for screening and eligibility, provide early detection and mitigation of adverse events, and serve as sensitive, specific, objective, and low participant burden efficacy endpoints. These measurements allow for meaningful integration of clinical trial data with real-world evidence, and provide the basis for movement toward patient-specific measures. Better measurement tools and the platforms to support them help HealthMode's partners make data-informed decisions, reduce uncertainty around enrollment and outcomes, de-risk development, and increase the speed at which novel therapeutics reach patients in need. The company was founded by Bradford Cross, Daniel R. Karlin. HealthMode was acquired by Mind Medicine (MindMed), Inc. on February 26, 2021 for $41.54 million. | Technology Services |
